Iftikhar Haissan, Suhail Anwar, Nathani Karim Rizwan, Urooba Amna, Shahzad Noman, Awan Sohail, Dhanani Rahim
Department of Surgery, Aga Khan University Hospital, Karachi, Sindh, Pakistan.
Section of Otolaryngology and Head and Neck Surgery, Aga Khan University Hospital, Karachi, Pakistan.
Int Arch Otorhinolaryngol. 2018 Oct;22(4):395-399. doi: 10.1055/s-0038-1641131. Epub 2018 Mar 29.
Critical weight loss is defined as an unintentional weight loss of ≥ 5% at 1 month or ≥ 10% at 6 months from the start of treatment. Critical weight loss leads to deterioration of the immune function and reduced tolerance to treatment (surgery ± radiochemotherapy) as well as increased complication rates. Critical weight loss, defined as a weight loss of ≥ 5% after 1 month or ≥ 10% after 6 months from the start of treatment, is not uncommon in head and neck cancer patients. We aimed to assess the factors associated with critical weight loss during the treatment of oral cavity squamous cell carcinoma patients. A retrospective cohort study was performed at the Aga Khan University Hospital, in Karachi, Pakistan, on 125 patients. Patients receiving adjuvant therapy were considered exposed, and the outcome was critical weight loss. The mean age of presentation was 46.9 ± 12.8 years in patients undergoing surgery and adjuvant therapy, with 119 (79.3%) of them being male and 31 (20.7%) female. One hundred and twelve patients (81.3%) developed critical weight loss at 6 months from the start of treatment, and the only significant variable associated with critical weight loss was the stage of the disease ( = 0.03). A large proportion of patients with oral cancer developed critical weight loss requiring a need for intervention. The overall stage of the disease is a significant predictor of critical weight loss in patients undergoing treatment.
临界体重减轻定义为从治疗开始起1个月内非故意体重减轻≥5%或6个月内≥10%。临界体重减轻会导致免疫功能恶化、对治疗（手术±放化疗）的耐受性降低以及并发症发生率增加。临界体重减轻定义为从治疗开始起1个月后体重减轻≥5%或6个月后≥10%，在头颈癌患者中并不少见。我们旨在评估口腔鳞状细胞癌患者治疗期间与临界体重减轻相关的因素。在巴基斯坦卡拉奇的阿迦汗大学医院对125例患者进行了一项回顾性队列研究。接受辅助治疗的患者被视为暴露组，结局为临界体重减轻。接受手术和辅助治疗的患者就诊时的平均年龄为46.9±12.8岁，其中119例（79.3%）为男性，31例（20.7%）为女性。112例患者（81.3%）在治疗开始后6个月出现临界体重减轻，与临界体重减轻相关的唯一显著变量是疾病分期（P = 0.03）。很大一部分口腔癌患者出现了需要干预的临界体重减轻。疾病的总体分期是接受治疗患者临界体重减轻的重要预测因素。
